Stock Track | Amphastar Pharmaceuticals Plunges 14.68% in Pre-Market on Earnings Miss and Analyst Target Price Cut
Stock Track
Feb 27
Amphastar Pharmaceuticals' stock experienced a significant pre-market plunge of 14.68% on Friday, extending losses from the previous trading session.
The sharp decline follows the company's release of fourth-quarter financial results that fell short of analyst expectations. Amphastar reported adjusted earnings per share of $0.73, missing the consensus estimate of $0.92, while revenue of $183.11 million also came in below expectations.
Adding to the negative sentiment, Jefferies cut its price target on Amphastar Pharmaceuticals to $30 from $38. The combination of disappointing earnings performance and the analyst downgrade prompted the substantial sell-off in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.